Peroxisome Proliferator-Activated Receptors: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
[[Image: 3dzy2.png|420px|left|thumb| Human PPARγ bound to RXRα and PPRE DNA strand, [[3dzy]]]] | [[Image: 3dzy2.png|420px|left|thumb| Human PPARγ bound to RXRα and PPRE DNA strand, [[3dzy]]]] | ||
{{STRUCTURE_3dzy| right| PDB=3dzy | SCENE=Peroxisome_Proliferator-Activated_Receptors/Ppar_opening4/1 |CAPTION= Crystal Structure of Human PPARγ, [[3dzy]] }} | {{STRUCTURE_3dzy| right| PDB=3dzy | SCENE=Peroxisome_Proliferator-Activated_Receptors/Ppar_opening4/1 |CAPTION= Crystal Structure of Human PPARγ, [[3dzy]] }} | ||
The [[Peroxisome Proliferator-Activated Receptors]] (PPAR) α, δ, and γ are members of the nuclear receptor family. Since their discovery in the early 90s, it has become clear that the PPARs are essential modulators of external stimuli, acting as transcription factors to regulate mammalian metabolism, cellular differentiation, and tumorigenesis. The PPARs are the targets of numerous pharmaceutical drugs aimed at treating [http://en.wikipedia.org/wiki/Hyperlipidemia hypolipidemia] and [[diabetes]] among other diseases.<ref | The [[Peroxisome Proliferator-Activated Receptors]] (PPAR) α, δ, and γ are members of the nuclear receptor family. Since their discovery in the early 90s, it has become clear that the PPARs are essential modulators of external stimuli, acting as transcription factors to regulate mammalian metabolism, cellular differentiation, and tumorigenesis. The PPARs are the targets of numerous pharmaceutical drugs aimed at treating [http://en.wikipedia.org/wiki/Hyperlipidemia hypolipidemia] and [[diabetes]] among other diseases.<ref name="Berger"/> | ||
<br /> | <br /> | ||